Human cytomegalovirus 65 kDa Phosphoprotein PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83 Pipeline Review, H1 2018
Summary
Human cytomegalovirus 65 kDa Phosphoprotein PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83 pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.
The latest report Human cytomegalovirus 65 kDa Phosphoprotein Pipeline Review, H1 2018, outlays comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Human cytomegalovirus 65 kDa Phosphoprotein PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83 65kDa cytosolic phosphoprotein pp65 counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus.
It participates in the transactivation of viral major immediateearly genes by the recruitment of host IFI16 to the promoter of these genes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 1, 1 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively.
Report covers products from therapy areas Infectious Disease, Oncology and Immunology which include indications Cytomegalovirus HHV5 Infections, Glioblastoma Multiforme GBM, Brain Tumor, Hematological Tumor, Human Immunodeficiency Virus HIV Infections AIDS, Kidney Transplant Rejection, Liver Transplant Rejection, Medulloblastoma, Recurrent Glioblastoma Multiforme GBM and Transplant Rejection.
Furthermore, this report also reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83
The report reviews Human cytomegalovirus 65 kDa Phosphoprotein PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83 targeted therapeutics and enlists all their major and minor projects
The report assesses Human cytomegalovirus 65 kDa Phosphoprotein PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope